Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

(2013) Karoline Kollmann et al.   CANCER CELL

Molecular mechanisms underlying RB protein function

(2013) Frederick A. Dick et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs

(2013) Tyler J. W. Robinson et al.   PLoS One

The Requirement for Cyclin D Function in Tumor Maintenance

(2012) Yoon Jong Choi et al.   CANCER CELL

Differentially Expressed Genes Regulating the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer

(2012) S. Lee et al.   CANCER RESEARCH

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

(2012) A. Kathleen McClendon et al.   CELL CYCLE

RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer

(2012) A. K. Witkiewicz et al.   CLINICAL CANCER RESEARCH

Retinoblastoma and Phosphate and Tensin Homolog Tumor Suppressors: Impact on Ductal Carcinoma In Situ Progression

(2012) Erik S. Knudsen et al.   JNCI-Journal of the National Cancer Institute

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA

(2012) S. Volinia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Association of RB/p16-Pathway Perturbations with DCIS Recurrence

(2011) Agnieszka K. Witkiewicz et al.   AMERICAN JOURNAL OF PATHOLOGY

Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia

(2011) Erik S. Knudsen et al.   BREAST CANCER RESEARCH AND TREATMENT

A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

(2011) Lars Anders et al.   CANCER CELL

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer

(2011) Zhe Jiang et al.   CELL CYCLE

The meaning of p16ink4aexpression in tumors

(2011) Agnieszka K. Witkiewicz et al.   CELL CYCLE

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

(2011) C. Thangavel et al.   ENDOCRINE-RELATED CANCER

CpG island hypermethylation ofBRCA1and loss of pRb as co-occurring events in basal/triple-negative breast cancer

(2011) Olafur Andri Stefansson et al.   Epigenetics

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway

(2011) Patrick Viatour et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

(2011) T. W. Miller et al.   Cancer Discovery

Treatment of HER2-overexpressing breast cancer

(2010) J. Baselga   ANNALS OF ONCOLOGY

Specific Killing of Rb Mutant Cancer Cells by Inactivating TSC2

(2010) Binghui Li et al.   CANCER CELL

Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence

(2010) Agustin Chicas et al.   CANCER CELL

RB-pathway disruption in breast cancer

(2010) Adam Ertel et al.   CELL CYCLE

Targeting the RB-pathway in Cancer Therapy

(2010) E. S. Knudsen et al.   CLINICAL CANCER RESEARCH

Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status

(2010) Zhe Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009

(2010) C. J. Allegra et al.   JNCI-Journal of the National Cancer Institute

Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis

(2010) K. Kerlikowske et al.   JNCI-Journal of the National Cancer Institute

Transcriptional role of cyclin D1 in development revealed by a genetic–proteomic screen

(2010) Frédéric Bienvenu et al.   NATURE

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Most Basal-like Breast Carcinomas Demonstrate the Same Rb−/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically

(2009) Andrea Proctor Subhawong et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy

(2009) D. Trere et al.   ANNALS OF ONCOLOGY

Local Excision Alone Without Irradiation for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Cooperative Oncology Group

(2009) Lorie L. Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

Rb Depletion Results in Deregulation of E-Cadherin and Induction of Cellular Phenotypic Changes that Are Characteristic of the Epithelial-to-Mesenchymal Transition

(2008) Y. Arima et al.   CANCER RESEARCH